Lenzing's Two-Speed Makeover: Raising €600m While Cutting 2,000 Jobs

Lenzing raises €600M and cuts 2,000 jobs to pivot to nonwovens, but shares lag as investors weigh transformation costs.

There is a peculiar moment in a company's life when contraction and expansion happen at the same time. Lenzing, the Austrian fibre maker, is living through exactly that paradox — and its share price, trading below its key moving averages for a month, suggests investors are still trying to decide which half of the story matters more.

The mathematics of the current situation are stark. The Upper Austrian group has secured roughly €300 million in fresh equity through a capital increase approved at an extraordinary general meeting in late August, with another €300 million coming from bank financing. That €600 million war chest stands against a market capitalisation of just €876.63 million — a substantial bet for a company of this size, and one that existing shareholders will help fund through subscription rights that protect their proportional stakes.

The Human Cost of Restructuring

The other side of that equation is a capacity reduction that carries a heavy social price tag. Management confirmed at the end of July that fibre production at Heiligenkreuz in Burgenland will cease by the end of 2026, with the Grimsby site in England following in 2027. Around 2,000 jobs worldwide are affected — not a cosmetic trim but a structural break that echoes what is happening across European basic industries grappling with high energy costs and relentless Asian competition.

The strategy has a name that reveals its intent: "Grow Nonwovens, Reset Textiles." The plan is to expand the nonwovens business organically while narrowing traditional textile fibre operations to premium segments. The pulp and biorefinery division is also earmarked for strengthening. In essence, Lenzing is trying to transform itself from a volume player into a value player — ambitious, though not without logic given the competitive pressures.

A New Leadership Team Takes the Reins

The governance overhaul accompanying this transition is equally significant. Georg Kasperkovitz took over as chief executive in early June, joined by CFO Mathias Breuer and CPO/CTO Christian Skilich. At supervisory board level, Martin Seiter has succeeded Franz Gasselsberger, who stepped down at his own request. A completely renewed leadership team is thus taking charge precisely when decisions about plant closures and workforce reductions are being made — a challenging assignment, though possibly the right constellation for a genuine fresh start.

Interim Results Offer Some Encouragement

The half-year figures released roughly three weeks ago give management at least short-term justification for their approach. Net profit more than doubled to €35.6 million from €15.2 million in the prior-year period. Revenue reached €1.27 billion, with EBITDA of €239.2 million and free cash flow of €45.8 million — numbers that suggest a company emerging from crisis.

Yet the share price has slipped about 2.4 percent since those results, and the monthly decline stands at 4.0 percent. The market, it seems, had already priced in the operational recovery and is now focused on the costs of transformation. Those costs are real: plant closures, social plans, and dilution from the capital increase.

A Market Waiting for Proof

The stock currently trades at €22.65, roughly 24 percent below its 52-week high of €29.75 from June, though still 17 percent above the March low of €19.40. The relative strength index of 42 signals neither overbought nor oversold conditions. The gap to the 200-day moving average of €24.13 stands at more than 6 percent in negative territory — a clear indication that the shares remain below their medium-term trend lines.

The timeline for the capital increase runs until 25 February 2027 at the latest, giving investors a defined window in which to measure progress. For shareholders, the bet is on a company that is shrinking radically in order to emerge stronger — a wager that will only be settled when the next set of numbers demonstrates whether this dual strategy of cutting capacity while raising capital can actually deliver the promised margin improvement.